Former Cigna exec warns of lobbying power by insurance industry

A former insurance executive is speaking up against the lobbying power of the health insurance industry as the issue of healthcare reform in the 2020 election heats up in the Democratic debates.

Penning an essay for NBC News’ opinion and essays section THINK, Wendell Potter, former vice president for corporate communication at Cigna, explained how he worked to undermine universal healthcare for decades in order to protect the bottom line of his employer.

Potter called out the Healthcare Leadership Council, a Washington, D.C.-based group formed by big insurance, hospital, drug and medical device company executives to lobby against healthcare reform proposals. Specifically, the group targeted President Bill Clinton’s proposed health reform, the Health Security Act, headed by Hillary Clinton.

Thanks to the group’s efforts, the bill never even saw a vote in Congress. Twenty-five years later, Democratic presidential candidates are discussing similar reforms and universal healthcare as part of their platforms at the same time as the uninsured rate is rising again. As the issue continues to loom larger in the upcoming election, Potter sees language direct from insurance lobbyists being injected into the national rhetoric––language he helped create to scare Americans away from universal healthcare reform.

“I feel compelled to speak up and help set the record straight when so many politicians and journalists are using talking points that come straight from health insurance central casting scripts,” he wrote.

See the full essay below:

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.